Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Patients with severe dystrophic epidermolysis bullosa, or EB, have skin so fragile, the slightest touch can lead to ...

Scientists from MIT have discovered that the teenage years are the key window when acne-linked bacteria take hold on our ...

The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.

The most common dermatologic conditions diagnosed for patients with skin of color differed from those patients’ top reported ...

The composition of bacterial populations living on our faces plays a significant role in the development of acne and other ...

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.

The U.S. Food and Drug Administration (FDA) has approved Abeona Therapeutics Inc.’s ZEVASKYN gene-modified cellular sheets.

The U.S. Food and Drug Administration has approved Abeona Therapeutics' Zevaskyn (prademagene zamikeracel) for patients with ...

Abeona has won FDA approval for Zevaskyn, setting up a commercial challenge to Krystal Biotech in the rare skin disease ...

With FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis ...

Patients with the debilitating dermatologic condition are born with COL7A1 mutations in both gene copies, affecting the ...